Here is the design of a clinical trial:

Official Title: The Combination of Hypofractionated Stereotactic Radiotherapy and Chemoradiotherapy Using Intensity-Modulated Radiotherapy for Newly Diagnosed Glioblastoma Multiforme: A Prospective, Single-Center, Single-Arm Phase II Clinical Trial

Included conditions:
- Glioma, Malignant

Study Armgroups:
- {'label': 'HSRT+IMRT+Temozolomide', 'type': 'EXPERIMENTAL', 'description': '* Intensity-modulated radiotherapy 20Gy/10fx, 5 days a week for 2 weeks.\n* Hypofractionated stereotactic radiotherapy 30Gy/5fx, 5 days a week for 1 week.\n* Temozolomide once daily (75mg/m2/d) orally administered concurrently with radiotherapy.', 'interventionNames': ['Device: Radiation', 'Drug: Temozolomide']}

Interventions:
- {'type': 'DEVICE', 'name': 'Radiation', 'description': 'Intensity-modulated radiotherapy 20Gy/10fx', 'armGroupLabels': ['HSRT+IMRT+Temozolomide']}
- {'type': 'DEVICE', 'name': 'Radiation', 'description': 'Hypofractionated Stereotactic Radiotherapy 30Gy/5fx', 'armGroupLabels': ['HSRT+IMRT+Temozolomide']}
- {'type': 'DRUG', 'name': 'Temozolomide', 'description': 'Temozolomide 75 mg/m2 concurrently administered with RT.', 'armGroupLabels': ['HSRT+IMRT+Temozolomide']}

Primary Outcomes:
- {'measure': 'Overall survival (OS)', 'description': 'Estimated using the Kaplan-Meier method', 'timeFrame': 'From the start of treatment to the date of death or the last follow-up, up to approximately 24 months'}

Please estimate the sample size based on the assumption: 
80% power, 0.050 significance level, 10% loss to follow-up
Sample size and power justification
        The design will be a prospective single-arm phase II trial to determine the effectiveness and safety of HSRT plus chemoradiotherapy after surgery for GBM. A two-sided, one-sample log-rank test calculated from a sample of 45 subjects achieves 80% power at a 0.050 significance level to detect a hazard ratio of 0.580 when the median survival time of the historic control group is 14Â months. Subjects are accrued for 12Â months. Follow-up continues for 24Â months after the last subject is added. Assuming a 10% loss to follow-up, the actual sample size will be 50.